Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2017 | Pages:
129 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Uveal Melanoma - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uveal Melanoma - Pipeline Review, H1 2017, provides an overview of the Uveal Melanoma (Oncology) pipeline landscape. Uveal melanoma, the most common intraocular tumor, is a disease in which cancer (malignant) cells are found in the part of the eye called the uvea. The uvea contains cells called melanocytes. When these cells become cancerous, the cancer is called a melanoma. Symptoms include dark spot on the iris, glaucoma, eye pain and eye redness. Uveal melanoma is more common in people who have atypical mole syndrome, dysplastic nevus syndrome, and ocular or oculodermal melanocytosis. Treatment includes surgery, radiation and proton therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uveal Melanoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Uveal Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Uveal Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Uveal Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 9, 6, 1 and 6 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 1, 1 and 1 molecules, respectively. Uveal Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Uveal Melanoma (Oncology). - The pipeline guide reviews pipeline therapeutics for Uveal Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Uveal Melanoma (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Uveal Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Uveal Melanoma (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Uveal Melanoma (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Uveal Melanoma (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Uveal Melanoma - Overview Uveal Melanoma - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Uveal Melanoma - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Uveal Melanoma - Companies Involved in Therapeutics Development Bellicum Pharmaceuticals Inc Bristol-Myers Squibb Company Celldex Therapeutics Inc Cleveland BioLabs Inc Delcath Systems Inc Eli Lilly and Company Iconic Therapeutics Inc Immunocore Ltd Lion Biotechnologies Inc Navigen Inc Novartis AG PEP-Therapy SAS Pfizer Inc Polaris Pharmaceuticals Inc Spectrum Pharmaceuticals Inc Syndax Pharmaceuticals Inc Uveal Melanoma - Drug Profiles AU-011 - Drug Profile Product Description Mechanism Of Action R&D Progress BPX-701 - Drug Profile Product Description Mechanism Of Action R&D Progress Cellular Immunotherapy for Metastatic Uveal Melanoma - Drug Profile Product Description Mechanism Of Action R&D Progress Cellular Immunotherapy to Target Melan-A, MAGE-3 and Survivin for Melanoma and Uveal Melanoma - Drug Profile Product Description Mechanism Of Action R&D Progress crizotinib - Drug Profile Product Description Mechanism Of Action R&D Progress emibetuzumab - Drug Profile Product Description Mechanism Of Action R&D Progress entinostat - Drug Profile Product Description Mechanism Of Action R&D Progress entolimod - Drug Profile Product Description Mechanism Of Action R&D Progress glembatumumab vedotin - Drug Profile Product Description Mechanism Of Action R&D Progress hI-con1 - Drug Profile Product Description Mechanism Of Action R&D Progress HPH-196 - Drug Profile Product Description Mechanism Of Action R&D Progress HPH-211 - Drug Profile Product Description Mechanism Of Action R&D Progress IMCgp-100 - Drug Profile Product Description Mechanism Of Action R&D Progress ipilimumab + nivolumab - Drug Profile Product Description Mechanism Of Action R&D Progress KCN-1 - Drug Profile Product Description Mechanism Of Action R&D Progress LXS-196 - Drug Profile Product Description Mechanism Of Action R&D Progress melphalan - Drug Profile Product Description Mechanism Of Action R&D Progress merestinib - Drug Profile Product Description Mechanism Of Action R&D Progress NAV-2729 - Drug Profile Product Description Mechanism Of Action R&D Progress nutlin-3 - Drug Profile Product Description Mechanism Of Action R&D Progress pasireotide ER - Drug Profile Product Description Mechanism Of Action R&D Progress pegargiminase - Drug Profile Product Description Mechanism Of Action R&D Progress PEP-010 - Drug Profile Product Description Mechanism Of Action R&D Progress sotrastaurin acetate - Drug Profile Product Description Mechanism Of Action R&D Progress sunitinib malate - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress vincristine sulfate - Drug Profile Product Description Mechanism Of Action R&D Progress Uveal Melanoma - Dormant Projects Uveal Melanoma - Discontinued Products Uveal Melanoma - Product Development Milestones Featured News & Press Releases Nov 09, 2016: Immunocore Presents Positive Monotherapy Data in Uveal Melanoma at the Society for Melanoma Research (SMR) 2016 Congress Apr 18, 2016: Celldex Therapeutics Presents data on Glembatumumab Vedotin at AACR 2016 Mar 30, 2016: Immunocore's IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma Jan 25, 2016: Immunocore's IMCgp100 Granted Orphan Drug Designation by US FDA for the Treatment of Uveal Melanoma Jan 11, 2016: Bellicum Pharmaceuticals Announces Submission of BPX-701 Clinical Trial Protocols for Review by the NIH RAC Sep 09, 2015: Immunocore's IMCgp100 Accepted for Adaptive Pathway Pilot Programme Jun 29, 2015: Lilly and Immunocore To Conduct Phase Ib/II Clinical Trial Collaboration For Treatment Of uveal melanoma May 22, 2015: Additional Tumor Type Cohorts Added to the Ongoing Phase 1 Study Combining ADI-PEG 20 with Cisplatin and Pemetrexed Based on New Research Results May 21, 2015: FDA Grants Orphan Drug Designation to Aura Biosciences' Novel Treatment for Uveal Melanoma Apr 14, 2015: Navigen Announces Phase I SBIR Award to Support Development of Uveal Melanoma Therapy Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Uveal Melanoma, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Uveal Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2017 Uveal Melanoma - Pipeline by Bristol-Myers Squibb Company, H1 2017 Uveal Melanoma - Pipeline by Celldex Therapeutics Inc, H1 2017 Uveal Melanoma - Pipeline by Cleveland BioLabs Inc, H1 2017 Uveal Melanoma - Pipeline by Delcath Systems Inc, H1 2017 Uveal Melanoma - Pipeline by Eli Lilly and Company, H1 2017 Uveal Melanoma - Pipeline by Iconic Therapeutics Inc, H1 2017 Uveal Melanoma - Pipeline by Immunocore Ltd, H1 2017 Uveal Melanoma - Pipeline by Lion Biotechnologies Inc, H1 2017 Uveal Melanoma - Pipeline by Navigen Inc, H1 2017 Uveal Melanoma - Pipeline by Novartis AG, H1 2017 Uveal Melanoma - Pipeline by PEP-Therapy SAS, H1 2017 Uveal Melanoma - Pipeline by Pfizer Inc, H1 2017 Uveal Melanoma - Pipeline by Polaris Pharmaceuticals Inc, H1 2017 Uveal Melanoma - Pipeline by Spectrum Pharmaceuticals Inc, H1 2017 Uveal Melanoma - Pipeline by Syndax Pharmaceuticals Inc, H1 2017 Uveal Melanoma - Dormant Projects, H1 2017 Uveal Melanoma - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
